Related references
Note: Only part of the references are listed.Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri et al.
LANCET (2015)
Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease
Veronique S. Chachay et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease
Forouzan Faghihzadeh et al.
NUTRITION RESEARCH (2014)
High-Dose Resveratrol Supplementation in Obese Men An Investigator-Initiated, Randomized, Placebo-Controlled Clinical Trial of Substrate Metabolism, Insulin Sensitivity, and Body Composition
Morten M. Poulsen et al.
DIABETES (2013)
Calorie Restriction-like Effects of 30 Days of Resveratrol Supplementation on Energy Metabolism and Metabolic Profile in Obese Humans
Silvie Timmers et al.
CELL METABOLISM (2011)
Share Paper
